We are delighted to welcome 9 world-class speakers at our FL Summit and look forward to hearing their thoughts and insights, as we discuss the key issues and opportunities facing the FL community.
Serves on the House of Lords International Relations and Defence Committee in the UK Parliament. He was formerly a Shadow Minister of Business, International Trade and Science and Innovation. He is Chairman Designate of 888 Holdings Plc and a Senior Adviser to Value Retail Plc.
Dr Smith earned his Medical Degree and PhD at Case Western Reserve University School of Medicine, Cleveland, OH. His Fellowship in Medical Oncology was at Memorial Sloan-Kettering Cancer Centre, NY where he also was a Fellow in Biomedical Research in the Clinical Scholars Program. He is Board-certified in Internal Medicine, Haematology and Medical Oncology. His clinical and laboratory interests have focused on targeted approaches to improve therapy of lymphoid malignancies. He has been involved in numerous clinical trials of targeted therapies, including CAR-T cells, in lymphoma, leukaemia and myeloma.
Gideon Rechavi was born in Israel. He received an MD from Tel-Aviv University in 1981 and PhD from the Weizmann Institute of Science in 1987. He is board certified in Haematology, Paediatrics, and Paediatric Haematology-Oncology. He is Professor of Haematology and holds the Djerassi Chair in Oncology, Tel Aviv University. Prof. Rechavi is a member of the European Academy of Cancer Sciences. He has published more than 465 articles in prestigious journals. His main research interests are RNA epigenetics, transposable genetic elements and cancer genomics with special emphasis on paediatric cancer.
He has helped develop a number of the agents now approved to treat lymphoma — including 131I-tositumomab/tositumomab, bortezomib, and pralatrexate — and through clinical studies he is evaluating the benefits of novel combinations of agents. In another area of research, he is working to improve the prognostic value of patients’ pathology specimens using computer-aided image analysis. He has published more than 100 papers on lymphoma research in journals such as Blood, Journal of Clinical Oncology and Clinical Cancer Research.
Dr Davide Rossi is Deputy Head of the Division of Haematology of the Oncology Institute of Southern Switzerland IOSI and Head of the Laboratory of Experimental Haematology at the Institute of Oncology Research IOR in Bellinzona, Switzerland. Dr Rossi has established himself as a leader in his field and is author of 267 peer reviewed publications. His research field is the molecular pathogenesis and diagnosis of B-cell tumours and translation of biological information into markers for disease diagnosis and prognostication.
Dr Kedmi specializes in treatment of Hodgkin (HL) and Non-Hodgkin lymphoma (NHL) as well as chronic lymphocytic leukemia (CLL). She was recently named as Head of the Israel Lymphoma Group.
Dr Anat Globerson Levin leads the Immunology and advanced CAR-T cell therapy research lab. She did her PhD at Prof. Eshhar at The Weizmann Institute. For the past several years, she has been researching adaptive T-cell therapy for breast cancer, multiple myeloma, head and neck, and other cancer diseases in order to develop and improve the CAR-T cell treatment. This includes her latest development of the dual CAR-T for myeloma running in to a clinical trial soon. She has received several competitive grants from Varda & Boaz Dotan, SPARK IL, Kamin, ISF and personal research catalyst in women’s cancer from the Parasol Foundation.
Dr Roni Shouval completed an internal medicine residency and hematology fellowship at the Chaim Sheba Medical Center. He obtained a PhD in machine learning from the Bar Ilan University. He completed a Bone Marrow Transplantation advanced fellowship at Memorial Sloan Kettering and is an Assistant Attending on the BMT and Cellular Therapy Services. Dr Shouval’s research is focused on investigating mechanisms and determinants of toxicity and response to chimeric antigen receptor (CAR) T-cell and hematopoietic cell transplantation (HCT) recipients. He uses various of computational methods on multiple data sources (genomics, microbiome) to identify potential therapeutic targets that would benefit patient care.
Yona Geffen joined Gamida Cell’s leadership team in December 2020, bringing over two decades of experience in leading clinical and drug development in the biotechnology and pharmaceutical industry. Prior to that, Yona served in different positions including Vice President, research and development at Stem Cell Medicine, Vice President, research and validation at Compugen and several roles including Senior Vice President, clinical development, Chief Operations Officer and Chief Executive Officer at Avraham Pharmaceuticals. Yona holds a Ph.D. in immunology and microbiology and an M.Sc. in business management from the Ben-Gurion University, Israel.